The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...
In December 2022, at the age of 33, Emily began suffering from severe bloating that made her appear "seven months pregnant".
Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...
At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...
OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...
JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...
The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...
Ovarian cancer drugs play a crucial role in the treatment ... Treatment options typically include chemotherapy, targeted therapies, immunotherapy, and hormone therapy. Chemotherapy remains a ...
"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果